submit to the journals

Lymphoma Journal Articles, Videos And Insights

Lymphoma:FEATURED Articles

flipper_slider

Lymphoma: Latest Articles

Lymphoma: INSIGHTS

The touchONCOLOGY website provides a selection of resources to inform clinicians and patients about the latest developments in the field. The following are quick, non peer-reviewed, opinion-based updates addressing current trends and opinion on the most recent advances in the area of oncology:

Lymphoma:FEATURED VIDEOS

Editor's choice

Editorial board member, Ian W Flinn from Sarah Cannon, Tennesse Oncology, in Nashville, TN, talks to us about risk of relapse and promising treatments for relapsed/refractory CLL and advances in the treatment of DLBCL and follicular lymphoma. 1. What are the most important unmet needs in the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL)? (0:11) 2. What do you consider the most promising treatments in clinical development for relapsed/refractory CLL? (0:51) 3. Can we predict in advance who is at high-risk to relapse and then modify therapy for these high-risk patients? (1:42) 4. What have been the most exciting recent developments in the treatment of diffuse large B-cell lymphoma (DLBCL)? (2:34) 5. What are the most exciting developments in the frontline treatment of follicular lymphoma? (3:26) Speaker disclosures: Ian W Flinn has nothing to disclose in relation to this video interview. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018

Lymphoma:Latest Videos

Video List based on Category on Node Page

Latest Videos

Annalisa Chiapella from Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino in Italy talks to touchONCOLOGY about patients with diffuse large B-cell lymphoma (DLBCL) with a TP53 mutation, and the aims and findings of the FIL-DLCL04 study to help tackle...
Martin Hutchings from Copenhagen University Hospital discusses the ECHELON-1 trial and treatment strategies in Hodgkin's lymphoma. 1. What are the limitations of current ABVD chemotherapy regimes for advanced Hodgkin’s lymphoma? (0:10) 2. Could you tell us a little about the...
Editorial board member, Ian W Flinn from Sarah Cannon, Tennesse Oncology, in Nashville, TN, talks to us about risk of relapse and promising treatments for relapsed/refractory CLL and advances in the treatment of DLBCL and follicular lymphoma. 1. What are the most important unmet needs...
Joseph M Connors discusses the rationale, design and results of the ECHELON-1 study of combined brentuximab vedotin and chemotherapy.
Wojciech Jurczak discusses the two phase III trials of rituximab biosimilars published earlier this year and how the European approval of rituximab biosimilars has impacted on follicular lymphoma treatment.
Matthew J Matasar discusses the challenges of treating patients with lymphoma and the role of antibody-drug conjugates in the treatment regimen.

LATEST TWEETS

Conference Highlights